

## SUPPLEMENTARY LISTING PARTICULARS DATED 23 FEBRUARY 2024



### **HSBC Bank plc**

*(a company incorporated in England with registered number 14259; the liability of its members is limited)*

*as Issuer*

### **HSBC Bank Middle East Limited**

*(a company limited by shares incorporated in the Dubai International Financial Centre)*

*as Issuer*

### **HSBC Continental Europe**

*(a société anonyme registered in France)*

*as Issuer*

## **PROGRAMME FOR THE ISSUANCE OF NOTES AND WARRANTS**

This supplement (the "**Supplement**") to the offering memorandum dated 1 June 2023 and the supplementary listing particulars thereto dated 3 August 2023, 4 August 2023 and 2 October 2023 relating to the Programme for the Issuance of Notes and Warrants (together, the "**Offering Memorandum**") prepared by HSBC Bank plc ("**HBEU**"), HSBC Bank Middle East Limited ("**HBME**") and HSBC Continental Europe ("**HBCE**" and, together with HBEU and HBME, the "**Issuers**" and each an "**Issuer**"), which constitutes listing particulars for the purposes of listing ("**Listing**") on the Official List of the Irish Stock Exchange plc trading as Euronext Dublin ("**Euronext Dublin**") and trading on the Global Exchange Market of Euronext Dublin and, for the avoidance of doubt, which does not constitute (i) a prospectus for the purposes of Part VI of the Financial Services and Markets Act 2000 (as amended) or (ii) a base prospectus for the purposes of Regulation (EU) 2017/1129, constitutes supplementary listing particulars (pursuant to rule 3.10 of the Global Exchange Market Listing and Admission to Trading Rules) for the purposes of Listing.

Terms defined in the Offering Memorandum have the same meaning when used in this Supplement.

This Supplement is supplemental to, and should be read in conjunction with, the Offering Memorandum and any other supplements to the Offering Memorandum prepared by the Issuers, in relation to their Programme for the Issuance of Notes and Warrants.

This Supplement has been approved by Euronext Dublin for the purposes of Listing.

HBME accepts responsibility for the information contained in this Supplement relating to HBME and Notes and Warrants issued by it. To the best of the knowledge of HBME (having taken all reasonable care to ensure that such is the case) the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.

The purpose of this Supplement is to:

- disclose that on 21 February 2024, HBME published the annual report and accounts for HBME and its subsidiaries for the year ended 31 December 2023 (the "**HBME 2023 Annual Report and Accounts**"), which contains the audited consolidated financial statements of HBME and the independent auditor's report thereon, in respect of the financial year ended 31 December

2023. The HBME 2023 Annual Report and Accounts is available at <https://www.hsbc.com/investors/results-and-announcements/all-reporting/subsidiaries?page=1&take=20>. The HBME 2023 Annual Report and Accounts is hereby incorporated by reference into the Offering Memorandum; and

- replace paragraph 11 of the '*General Information*' section of the Offering Memorandum with the following statement:

"There has been no significant change in the financial or trading position of HBME and its subsidiaries nor any material adverse change in the prospects of HBME since 31 December 2023."

To the extent that any document or information incorporated by reference itself incorporates any information by reference, either expressly or impliedly, such information will not form part of this Supplement or the Offering Memorandum, except where such information or documents are stated within this Supplement as specifically being incorporated by reference or where this Supplement is specifically defined as including such information. To the extent that only certain parts of the above documents are specified to be incorporated by reference herein, the non-incorporated parts of such documents are either not relevant for investors or covered elsewhere in this Supplement or the Offering Memorandum.

To the extent that there is any inconsistency between (a) any statement in this Supplement or any statement incorporated into the Offering Memorandum by this Supplement and (b) any other statement in or incorporated by reference in the Offering Memorandum, the statements in this Supplement will prevail.

HBME confirms that, save as disclosed in this Supplement, no significant new factor, material mistake or inaccuracy relating to information included in the Offering Memorandum and relating to HBME and Notes and Warrants issued by it under the Programme has arisen or been noted, as the case may be, since the publication of the Offering Memorandum.